QuantHealth (see Pulse 2.0 profile here) – an AI-powered clinical trial design startup – recently announced a major product upgrade to its platform to simulate trials at scale and expedite, de-risk and optimize drug development. Katina provides clinical researchers with an AI-guided workflow that simulates hundreds of thousands of potential trial protocol combinations of patient groups, treatment parameters, and different endpoints to maximize the trial success probability while considering additional operational and commercial considerations.
Katina is now integrated into QuantHealth’s platform for clinical trial design -powered by QuantHealth’s proprietary generative AI that is trained on real-world data from 350 million patients, large biomedical knowledge-graphs, and clinical trial data and can generate synthetic trial data for trial simulation, and boasts endpoint prediction accuracy of 86% for investigational therapies.
And Katina utilizes this proprietary AI technology to test hundreds of thousands of protocols in a simple, easy-to-use search mechanism that enables researchers to select protocols based on AI-generated recommendations or what interests them, drill into each for more information, and compare and contrast them against the standard of care. Upon trial simulation, protocols are assigned different scores and include additional insights based on existing data to help researchers more easily decide which protocols will work best for their specific trial and disease focus.
This new era of clinical trial optimization – powered by AI and massive real-world patient data – stands to benefit legacy pharmaceutical companies, emerging precision medicine innovators, and patients. And pharmaceutical companies can design better trials for new and existing compounds and attract and enroll the right patients for a more compelling, data-driven experience. Plus, precision medicine innovators – already using AI to inform drug discovery – can expand upon and digitally validate their ability to select the most responsive patients for trials, helping them market their services to pharmaceutical partners. Ultimately, patients will benefit the most as more patients will be enrolled in trials that were designed with their real-world experience in mind and with more precision and accuracy than humans could do alone, improving trial transparency and outcomes.
QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. And QuantHealth’s latest product innovation comes on the heels of the company raising a $15 million Series A funding round co-led by Bertelsmann Investments and Pitango HealthTech, with participation from existing investors Shoni Top Ventures and Nina Capital.
KEY QUOTE:
“This release is a game changer for protocol design committees and portfolio optimization teams. Today, these teams facilitate a painstaking negotiation process between the medical, commercial, operational, and regulatory stakeholders, that all need to weigh-in on the pros and cons of each protocol and portfolio decision. With the power of QuantHealth’s generative AI, and now further enhanced by monte-carlo workflow, the Katina platform fires off thousands of protocols at once and allows each stakeholder to evaluate the simulations based on what matters to them most- be it endpoint success, ability to recruit patients, likelihood of getting an approval, competitive performance, etc. This high-throughput, holistic approach ensures that when it comes to protocol selection and development strategy, no stone is left unturned, and all voices in the room are heard.”
— Orr Inbar, Co-Founder and CEO of QuantHealth
